The influence of short-term therapy of continous positive airway pressure (CPAP) on exhaled nitric oxide concentration (FENO) in patients with obstructive sleep apnea (OSA)

T. Przybylowski, P. Bielicki, M. Kumor, K. Hildebrand, R. Chazan (Warsaw, Poland)

Source: Annual Congress 2005 - Systemic effects of OSA
Session: Systemic effects of OSA
Session type: Thematic Poster Session
Number: 2316
Disease area: Airway diseases, Sleep and breathing disorders

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Przybylowski, P. Bielicki, M. Kumor, K. Hildebrand, R. Chazan (Warsaw, Poland). The influence of short-term therapy of continous positive airway pressure (CPAP) on exhaled nitric oxide concentration (FENO) in patients with obstructive sleep apnea (OSA). Eur Respir J 2005; 26: Suppl. 49, 2316

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Exhaled nitric oxide in obstructive sleep apnea (OSA) patients: short and long term response to automatic positive airway pressure (APAP) therapy
Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea
Year: 2007


Decreased plasma levels of nitric oxide (NO) derivatives in obstructive sleep apnea (OSA): response to automatic positive airway pressure (APAP) therapy
Source: Eur Respir J 2007; 30: Suppl. 51, 332s
Year: 2007

impact of continous positive airway pressure therapy on exhaled nitic oxide in obstructive sleep apnea syndrome
Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation
Year: 2019

Alveolar but not airway fractional exhaled nitric oxide concentration (FENO) is decreased in obstructive sleep apnea syndrome (OSAS)
Source: Eur Respir J 2003; 22: Suppl. 45, 467s
Year: 2003

Concentration of exhaled nitric oxide (FENO) in patients with obstructive sleep apnea
Source: Eur Respir J 2004; 24: Suppl. 48, 118s
Year: 2004

Effect of nasal CPAP on exhaled nitric oxide in patients with obstructive sleep apnea
Source: Eur Respir J 2007; 30: Suppl. 51, 332s
Year: 2007

Exhaled breath markers in patients with obstructive sleep apnea (OSA): baseline assessment and the impact of treatment with nasal continuous positive airway pressure
Source: Eur Respir J 2005; 26: Suppl. 49, 355s
Year: 2005

Influence of nasal obstruction (NO) on obstructive sleep apnea (OSA) severity and continuous positive airway pressure (CPAP) adaptation problems
Source: Annual Congress 2010 - The upper airway and oral appliances
Year: 2010

Oxydative stress in obstructive sleep apnea (OSA). Exhaled breath condensate (EBC) measurements (H2O2) in the follow-up of patients under CPAP. First results
Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea
Year: 2007


Plasma endothelin-1 (ET-1) levels in obstructive sleep apnea (OSA) patients and effect of continouous positive airway pressure (CPAP) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 40s
Year: 2005

Impact of humidification on compliance and side effects in obstructive sleep apnea (OSA) patients under auto continuous positive airway pressure (ACPAP) therapy
Source: Eur Respir J 2006; 28: Suppl. 50, 409s
Year: 2006

The influence of 3-weeks‘ therapy of continous positive airway pressure (CPAP) on serum leptin and homocysteine concentration in patients with obstructive sleep apnea (OSA)
Source: Annual Congress 2005 - Metabolic control in OSA
Year: 2005


Catecholamines and obstructive sleep apnea (OSA) severity: response to positive airway pressure (PAP) therapy
Source: Annual Congress 2009 - Continuous positive airway pressure therapy in obstructive sleep apnoea
Year: 2009


Effect of continuous positive airway pressure (CPAP) treatment on proangiogenic factors of angiogenesis in obstructive sleep apnea (OSA) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 39s
Year: 2005

Association between obstructive sleep apnea (OSA) and depression and the effect of continuous positive airway pressure (CPAP) treatment
Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology
Year: 2012


Effect of automatic positive airway pressure (APAP) therapy on blood pressure (BP) in patients with obstructive sleep apnea (OSA) and hypertension
Source: Annual Congress 2008 - Clinical aspects of continuous positive airway pressure therapy
Year: 2008


Effect of continuous positive airway pressure treatment (CPAP) in angiogenic growth factors‘ expression in patients with COPD and obstructive sleep apnea syndrome (OSAS)
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases
Year: 2010

Cough sensitivity, airway responsiveness and exhaled nitric oxide (eNO) for predicting the response to bronchodilator therapy (BDT) in patients with chronic non-productive cough
Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control
Year: 2010

Angiogenic factors in obstructive sleep apnea syndrome (OSA). Effects of nasal continuous positive airway pressure treatment (CPAP)
Source: Annual Congress 2010 - Biomarkers for oxidative stress, inflammation and cardiovascular function in sleep apnoea
Year: 2010


Positional obstructive sleep apnea (OSA) and automatic positive airway pressure (APAP) therapy
Source: Annual Congress 2012 - Technology, screening and questionnaires in OSA
Year: 2012